International Clinical Trial: A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract Cancer

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07854600) titled 'A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract Cancer' on Sept. 24.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Haitao Zhao, MD

Condition: Biliary Tract Cancer (BTC)

Intervention: Drug: Ivonescimab

Recruitment Status: Recruiting

Phase: Phase 2

Date of First Enrollment: October 2026

Target Sample Size: 87

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07854600

Publis...